title: Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.
abstract: After more than 30 years of iterations of surgical debulking plus chemotherapy, the need for complementary ovarian cancer treatments has become clear. In the ovarian cancer microenvironment, myeloid immunosuppressive leukocytes, lymphocytes, fibroblasts and endothelial cells, as well as their secreted products, surface molecules and paracrine survival factors, all provide opportunities for novel interventions. The potential of targeting microenvironmental elements in ovarian cancer patients is underscored by recently successful anti-angiogenic therapies. The compartmentalized nature of ovarian cancer, its immunogenicity and its accessibility make it an ideal disease for targeting non-tumor host cells. This review discusses the 'state-of-the-art' of the field, with an emphasis on the potential of modulating the activity of abundant microenvironmental immune cells, which govern both angiogenesis and immunosuppression.
authors.affiliation: Tumor Microenvironment and Metastasis Program. The Wistar Institute. Philadelphia, PA 19104, USA.
authors.forename: Uciane K
authors.initials: UK
authors.lastname: Scarlett
authors.forename: Jose R
authors.initials: JR
authors.lastname: Conejo-Garcia
keywords: Ovarian cancer; angiogenesis; dendritic cell; fibroblast; immunotherapy; tumor immunology; tumor microenvironment
references.citation: Cancer Res. 2012 Apr 1;72(7):1683-93
references.pmid: 22307839
references.citation: Cancer. 1993 Jan 15;71(2 Suppl):517-23
references.pmid: 8420671
references.citation: Breast Cancer Res Treat. 2012 Jun;133(2):799-804
references.pmid: 22418702
references.citation: Nat Rev Immunol. 2011 Sep 23;11(10):702-11
references.pmid: 21941296
references.citation: Nat Med. 2008 Jan;14(1):28-36
references.pmid: 18157142
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
references.pmid: 17360651
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: J Exp Med. 2004 Mar 15;199(6):775-84
references.pmid: 15007094
references.citation: Science. 2011 Mar 25;331(6024):1612-6
references.pmid: 21436454
references.citation: Cancer Res. 2012 Jan 1;72(1):66-75
references.pmid: 22065722
references.citation: Cancer Res. 2009 Sep 15;69(18):7329-37
references.pmid: 19738057
references.citation: N Engl J Med. 2003 Jan 16;348(3):203-13
references.pmid: 12529460
references.citation: Expert Opin Biol Ther. 2005 Sep;5(9):1193-210
references.pmid: 16120050
references.citation: Immunity. 2010 Jun 25;32(6):790-802
references.pmid: 20605485
references.citation: Mol Cancer Ther. 2012 Mar;11(3):517-25
references.pmid: 22351743
references.citation: Oncotarget. 2010 Sep;1(5):329-38
references.pmid: 21113407
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Immunol. 2010 May 15;184(10):5654-62
references.pmid: 20400704
references.citation: J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612
references.pmid: 21957230
references.citation: Nat Med. 2004 Sep;10(9):950-8
references.pmid: 15334073
references.citation: J Exp Med. 2012 Feb 13;209(2):201-9
references.pmid: 22330682
references.citation: Cancer Res. 2004 Mar 15;64(6):2175-82
references.pmid: 15026360
references.citation: Cancer Res. 2010 Oct 15;70(20):7764-75
references.pmid: 20924115
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4170-7
references.pmid: 17634545
references.citation: Hum Pathol. 2011 Jul;42(7):918-31
references.pmid: 21683865
references.citation: Cancer Res. 2009 Aug 1;69(15):6331-8
references.pmid: 19602595
references.citation: Oncologist. 2007 Jan;12(1):20-37
references.pmid: 17227898
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
references.pmid: 19211796
references.citation: Clin Cancer Res. 2008 May 1;14(9):2740-8
references.pmid: 18451240
references.citation: J Clin Invest. 2009 Aug;119(8):2231-44
references.pmid: 19620771
references.citation: Blood. 2009 Aug 6;114(6):1141-9
references.pmid: 19470694
references.citation: Cell Cycle. 2011 Feb 1;10(3):368-9
references.pmid: 21270530
references.citation: Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21
references.pmid: 16297528
references.citation: N Engl J Med. 2011 Dec 29;365(26):2473-83
references.pmid: 22204724
references.citation: N Engl J Med. 2011 Dec 29;365(26):2484-96
references.pmid: 22204725
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Clin Dev Immunol. 2010;2010:139304
references.pmid: 21076522
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
references.pmid: 16344461
references.citation: Cytokine. 1996 Jul;8(7):578-85
references.pmid: 8891439
references.citation: Blood. 2005 Jan 15;105(2):679-81
references.pmid: 15358628
references.citation: Future Oncol. 2009 Oct;5(8):1189-92
references.pmid: 19852731
references.citation: Cell Cycle. 2010 Jan 15;9(2):260-8
references.pmid: 20023378
references.citation: Blood. 2008 Mar 15;111(6):3116-25
references.pmid: 18202224
references.citation: Science. 2010 Nov 5;330(6005):827-30
references.pmid: 21051638
references.citation: Cancer J. 2010 Jul-Aug;16(4):348-53
references.pmid: 20693846
references.citation: J Exp Med. 2011 Mar 14;208(3):479-90
references.pmid: 21339324
references.citation: J Exp Med. 2012 Mar 12;209(3):495-506
references.pmid: 22351930
references.citation: Cancer Res. 2008 Sep 15;68(18):7684-91
references.pmid: 18768667
references.citation: Cancer Biol Ther. 2007 Aug;6(8):1302-12
references.pmid: 17712227
references.citation: Clin Cancer Res. 2010 Apr 15;16(8):2443-9
references.pmid: 20371685